In a report released on October 7, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $10.06.
Higgins covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Astria Therapeutics, and Eiger Biopharmaceuticals. According to TipRanks, Higgins has an average return of 6.0% and a 31.39% success rate on recommended stocks.
Astria Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.50, which is an 113.72% upside from current levels. In a report released on October 5, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
See the top stocks recommended by analysts >>
ATXS market cap is currently $139.4M and has a P/E ratio of -2.97.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
Read More on ATXS:
